Format

Send to

Choose Destination
J Allergy Clin Immunol Pract. 2014 Jan-Feb;2(1):70-6. doi: 10.1016/j.jaip.2013.09.004. Epub 2013 Dec 3.

The Mastocytosis Society survey on mast cell disorders: patient experiences and perceptions.

Author information

1
The Mastocytosis Society, Inc, Hastings, Neb.
2
Division of Rheumatology, Immunology, and Allergy, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass.
3
Division of Hematology and Hemostaseology, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria.
4
Division of Rheumatology, Immunology, and Allergy, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass. Electronic address: cakin@partners.org.

Abstract

BACKGROUND:

Mast cell diseases include mastocytosis and mast cell activation syndromes, some of which have been shown to involve clonal defects in mast cells that result in abnormal cellular proliferation or activation. Numerous clinical studies of mastocytosis have been published, but no population-based comprehensive surveys of patients in the United States have been identified. Few mast cell disease specialty centers exist in the United States, and awareness of these mast cell disorders is limited among nonspecialists. Accordingly, information concerning the experiences of the overall estimated population of these patients has been lacking.

OBJECTIVE:

To identify the experiences and perceptions of patients with mastocytosis, mast cell activation syndromes, and related disorders, The Mastocytosis Society (TMS), a US based patient advocacy, research, and education organization, conducted a survey of its members and other people known or suspected to be part of this patient population.

METHODS:

A Web-based survey was publicized through clinics that treat these patients and through TMS's newsletter, Web site, and online blogs. Both online and paper copies of the questionnaire were provided, together with required statements of consent.

RESULTS:

The first results are presented for 420 patients. These results include demographics, diagnoses, symptoms, allergies, provoking factors of mast cell symptoms, and disease impact.

CONCLUSION:

Patients with mastocytosis and mast cell activation syndromes have provided clinical specialists, collaborators, and other patients with information to enable them to explore and deepen their understanding of the experiences and perceptions of people coping with these disorders.

KEYWORDS:

AFIRMM; Allergy; Anaphylaxis; Association Française pour les Initiatives de Recherche sur le Mastocytes et les Mastocytoses; CM; Cutaneous mastocytosis; Food intolerance; IA; Idiopathic anaphylaxis; Ig; Immunoglobulin; Insect venom; MC; MCA; MCAD; MCAS; MCD; Mast cell; Mast cell activation; Mast cell activation disorder; Mast cell activation syndrome; Mast cell disorder; Mast cell disorders; RAST; REMA; Radioallergosorbent test; Red Española de Mastocitosis; SM; Survey; Systemic mastocytosis; TMEP; TMS; Telangiectasia macularis eruptiva perstans; The Mastocytosis Society; The Mastocytosis Society, Inc; Trigger; UP; Urticaria pigmentosa

PMID:
24565772
DOI:
10.1016/j.jaip.2013.09.004
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center